T 686

inhibits production of plasminogen activator inhibitor-1 (PAI-1); RN given for (E,E)-isomer; structure in first source

Also Known As:

3-benzylidene-4-(3,4,5-trimethoxybenzylidene)pyrrolidine-2,5-dione; T 686, (E,Z)-isomer; T 686, (Z,E)-isomer; T-686

Networked: 2 relevant articles (0 outcomes, 1 trials/studies)

Bio-Agent Context: Research Results

Organic Chemicals: 133
- Hydrocarbons: 1713
  - Cyclic Hydrocarbons: 97
    - Aromatic Hydrocarbons: 291
      - Benzene Derivatives: 17
        Benzylidene Compounds: 10
        T 686: 2
- Imides: 79
  - Succinimides: 11
    - T 686: 2
Heterocyclic Compounds: 198
- 1-Ring Heterocyclic Compounds
  - Pyrrolidines: 115
    - Pyrrolidinones: 162
      - Succinimides: 11
        T 686: 2

Related Diseases

1.	Thrombosis (Thrombus) 07/09/1997 - "These results suggest that T-686 prevents thrombus formation in rats without impairment of hemostasis." 07/09/1997 - "The aim of this study was to evaluate the antithrombotic potential of T-686 ((3E,4E)-3-benzylidene-4-(3,4,5-trimethoxy-benzylidene)-pyrr olidine-2,5-dione), a novel inhibitor of plasminogen activator inhibitor-1 (PAI-1), in rat thrombosis models. " 07/09/1997 - "In the arterio-venous shunt model, pretreatment with T-686 (10 mg/kg per day) or ticlopidine (100 mg/kg per day) for 8 days inhibited thrombus formation by 33% and 44%, respectively. " 07/09/1997 - "T-686, a novel inhibitor of plasminogen activator inhibitor-1, inhibits thrombosis without impairment of hemostasis in rats."
2.	Vascular System Injuries 02/15/1997 - "In rabbits with aortic atherosclerosis induced by hypercholesterolemia and implantation of indwelling plastic tubing, oral administration of T-686 (30mg/kg body weight/day) for 8 weeks attenuated the increase in plasma PAI-1 activity induced by vascular injury without decreasing blood triglyceride and cholesterol. "
3.	Atherosclerosis 02/15/1997 - "In rabbits with aortic atherosclerosis induced by hypercholesterolemia and implantation of indwelling plastic tubing, oral administration of T-686 (30mg/kg body weight/day) for 8 weeks attenuated the increase in plasma PAI-1 activity induced by vascular injury without decreasing blood triglyceride and cholesterol. "
4.	Thrombophilia 07/09/1997 - "T-686 (0.1-100 mg/kg per day, p.o.) dose dependently decreased the weight of venous thrombi induced by a combination of stasis and hypercoagulability. "
5.	Hypercholesterolemia 02/15/1997 - "In rabbits with aortic atherosclerosis induced by hypercholesterolemia and implantation of indwelling plastic tubing, oral administration of T-686 (30mg/kg body weight/day) for 8 weeks attenuated the increase in plasma PAI-1 activity induced by vascular injury without decreasing blood triglyceride and cholesterol. "

Related Drugs and Biologics

1.	Plasminogen Activators (Plasminogen Activator)
2.	Plasminogen Activator Inhibitor 1
3.	Triglycerides (Triacylglycerol)
4.	Ticlopidine (Ticlid)
5.	Plastics
6.	Cholesterol

Related Therapies and Procedures

1.	Oral Administration